Kanchana Leerunyakul

Kanchana Leerunyakul

Auto-generated profile, based on publicly available information

Kanchana Leerunyakul

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PSPoonkiat Suchonwanit
Poonkiat Suchonwanit
STSasima Thammarucha
Sasima Thammarucha
KLKanchana Leerunyakul
Kanchana Leerunyakul
Minoxidil was first introduced as an antihypertensive medication and the discovery of its common adverse event, hypertrichosis, led to the development of a topical formulation for promoting hair growth. To date, topical minoxidil is the mainstay treatment for androgenetic alopecia and is used as an off-label treatment for other hair loss conditions. Despite its widespread application, the exact mechanism of action of minoxidil is still not fully understood. In this article, we aim to review and update current information on the pharmacology, mechanism of action, clinical efficacy, and adverse events of topical minoxidil.

1 March 2020 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
WIWimolsiri Iamsumang
Wimolsiri Iamsumang
KLKanchana Leerunyakul
Kanchana Leerunyakul
PSPoonkiat Suchonwanit
Poonkiat Suchonwanit
The currently approved treatment for female pattern hair loss (FPHL) includes topical minoxidil administration; however, this treatment fails to achieve hair regrowth in some patients. Finasteride, a selective 5α-reductase inhibitor (5-ARI), may be considered as an alternative treatment. However, because of its potential teratogenic effects, clinical studies and use of finasteride for FPHL are limited. In this review, we aim to summarize the literature regarding the pharmacology, clinical efficacy, and adverse effects of oral finasteride for the treatment of FPHL and to provide novel therapeutic options including topical finasteride and dutasteride, a new generation 5-ARI, for the treatment of FPHL.

1 April 2020 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
KLKanchana Leerunyakul
Kanchana Leerunyakul
PSPoonkiat Suchonwanit
Poonkiat Suchonwanit
Asian hair is known for its straightness, dark pigmentation, and large diameter. The cuticle layer in Asians is thicker with more compact cuticle cells than that in Caucasians. Asian hair generally exhibits the strongest mechanical properties, and its cross-sectional area is determined greatly by genetic variations, particularly from the ectodysplasin A receptor gene. However, knowledge on Asian hair remains unclear with limited studies. This article aimed to review and summarize the characteristics and properties of Asian hair. It also aimed to discuss hair disorders including linear lupus panniculitis and pseudocyst of the scalp that occur distinctively in Asian populations.

1 September 2021 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
KCKumutnart Chanprapaph
Kumutnart Chanprapaph
TMThipprapai Mahasaksiri
Thipprapai Mahasaksiri
CKChaninan Kositkuljorn
Chaninan Kositkuljorn
KLKanchana Leerunyakul
Kanchana Leerunyakul
PSPoonkiat Suchonwanit
Poonkiat Suchonwanit
Background: Increased rates of autoimmune diseases (ADs) have been reported in association with alopecia areata (AA); however, the risk factors for coexisting ADs in AA patients have been poorly investigated. Objective: To evaluate the prevalence and factors associated with AD comorbidities in patients with AA. Methods: This case–control study included patients diagnosed with AA between January 2000 and March 2020. Individuals with AA, both with and without concomitant ADs, were statistically compared. Variables significantly associated with coexisting ADs were identified using univariate and multivariate logistic regression analyses. Multinomial logistic regression analysis was performed to identify the specific risk factors for each concomitant AD. Results: Among the 615 patients with AA, comorbid ADs were found in 76 (12.4%). Autoimmune thyroid disease (AITD) exhibited the highest frequency (n = 42, 6.8%), followed by vitiligo (n = 15, 2.4%), and systemic lupus erythematosus (SLE) (n = 12, 2.0%). Logistic regression analyses revealed that female sex (odds ratio [OR] = 2.45, 95% confidence interval [CI] = 1.24– 4.82; P = 0.011), nail abnormalities (OR = 2.49, 95% CI = 1.14– 5.46; P = 0.023), and atopic diseases (OR = 1.98, 95% CI = 1.09– 2.43; P < 0.001) were significantly associated with coexisting ADs. Regarding each concomitant AD, nail abnormalities were an associated factor for AITD (OR = 4.65, 95% CI = 1.96– 7.24; P = 0.01), whereas coexisting atopic diseases were demonstrated as a predictor of vitiligo (OR = 2.48, 95% CI = 1.43– 4.58; P = 0.02). Female sex (OR = 1.61, 95% CI = 1.18– 4.27; P = 0.04) and family history of AD (OR = 1.85, 95% CI = 1.26– 4.19; P = 0.03) were predictors of SLE. Conclusion: This study suggests that female AA patients with nail abnormalities and atopic diseases have increased rates of AD comorbidities. A thorough review of systems for associated factors can help physicians screen for concomitant ADs.

26 June 2020 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
PSPoonkiat Suchonwanit
Poonkiat Suchonwanit
WIWimolsiri Iamsumang
Wimolsiri Iamsumang
KLKanchana Leerunyakul
Kanchana Leerunyakul
Background: Androgenetic alopecia (AGA) is a frequently encountered dermatological concern that impacts a patient’s self-esteem and quality of life. Finasteride is a selective 5-alpha reductase inhibitor that has been approved for the treatment of male AGA and the off-label use in female pattern hair loss (FPHL); however, its adverse effects may limit its use. Topical finasteride is a new formulation that aims to decrease complications caused by oral administration. Objective: This review assesses the pharmacology, current therapeutic use, and safety of topical finasteride for the treatment of AGA and FPHL. Methods: A PubMed search was conducted to include all English language articles on topical finasteride from January 1992 to January 2020. Results: A total of 33 articles including 28 topical finasteride related articles and five AGA related articles were included in this review. Multiple studies on topical finasteride as the treatment for male AGA and FPHL showed positive results with a favorable safety profile. Conclusions: Topical finasteride is a promising therapeutic option. We emphasize the importance of continued research for the establishment of a novel therapeutic agent.

11 March 2020 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
KLKanchana Leerunyakul
Kanchana Leerunyakul
STSasima Thammarucha
Sasima Thammarucha
PSPoonkiat Suchonwanit
Poonkiat Suchonwanit
SRSuthinee Rutnin
Suthinee Rutnin
Introduction: The treatment of recalcitrant nongenital cutaneous warts has always been challenging for dermatologists as they often recur and relapse. Multiple treatment options have been investigated to improve the outcome. This review provides an overview of the current treatment modalities and summarizes the efficacy and side effects of each treatment option for recalcitrant nongenital cutaneous warts. Methods: A PubMed search was performed through July 2019 to include all English language reports investigating the treatment for recalcitrant nongenital cutaneous warts, regardless of design. Results: A total of 144 studies were included in this review. The treatment options for recalcitrant nongenital cutaneous warts can be divided into three groups: destructive treatment, immunotherapy, and cytotoxic agents. Although both destructive therapies and cytotoxic agents demonstrated high complete response rates, immunotherapy, which is a minimally invasive method, was superior in terms of the clearance of distant warts. Intralesional mumps-measles-rubella injections and purified protein derivatives currently demonstrate high efficacy with well-established clinical evidence. Conclusions: Many upcoming treatment modalities, especially immunotherapy, are promising. However, more comparative studies are required to verify the efficacy and safety profile.